Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2024-05-23 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 at ASCO 2024
Regulatory Filings Classification · 92% confidence The document is a press release dated May 23, 2024, announcing that clinical data for the drug candidate BI-1808 will be presented at the ASCO 2024 meeting. It summarizes key efficacy and safety findings (CR, PR, SD) and mentions the combination therapy with KEYTRUDA. Crucially, the end of the document states: "The full poster will be posted to the company's website [...] shortly after the presentation." Furthermore, the document concludes with a section titled "Attachments" linking to a PDF of the presentation/release. This structure—a brief announcement detailing results and pointing to the full material or presentation shortly after release—is characteristic of an Earnings Release (ER) or, more generally, a Regulatory Filing (RNS) if it doesn't fit a specific financial report type. Since it is an announcement of clinical trial data and presentation details, and not the comprehensive financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) which often covers major operational/clinical milestones for biotech firms, or RNS as a general regulatory announcement. Given the focus on clinical data presentation, ER is a strong candidate, but RNS is the safest fallback for general corporate news releases that aren't explicitly financial results (ER) or management changes (MANG). However, biotech companies frequently use ER to announce significant clinical data updates. Since it is a press release announcing results and an upcoming presentation, and not the full financial report, I will classify it as an Earnings Release (ER) as it pertains to operational performance milestones, or RNS. Given the context of clinical trial updates, ER is often used for these announcements. I will lean towards ER as it contains key performance indicators (efficacy data).
2024-05-23 English
BioInvent presenterar lovande fas 1-data på ASCO 2024 för BI-1206 i kombination med KEYTRUDA® (pembrolizumab) i patienter med solida tumörer
Regulatory Filings Classification · 95% confidence The document is a press release dated May 23, 2024, announcing promising Phase 1 data for a drug candidate (BI-1206) to be presented at the ASCO 2024 annual meeting. It details clinical results (response rates, safety profile) and mentions that the full poster will be uploaded to the company website after the presentation. The text explicitly states, "Den fullständiga postern kommer att läggas upp på bolagets hemsida [...] strax efter presentationen." Furthermore, the document concludes with a section titled "Bifogade filer" which links to a PDF of the announcement itself, and it contains language typical of a regulatory disclosure ("Denna information är sådan information som BioInvent International är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning."). Since this is an announcement about upcoming data presentation and the actual detailed presentation/poster is mentioned as being released separately or later, and it is a general regulatory disclosure, it fits best under the general Regulatory Filings category (RNS), as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA). It is a general corporate update/disclosure.
2024-05-23 Swedish
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL
Earnings Release Classification · 95% confidence The document is a press release dated May 14, 2024, announcing that clinical data for the drug BI-1206 will be presented at the European Hematology Association (EHA) congress in June 2024. It details preliminary efficacy and safety results (e.g., ORR, CRR, TEAEs) from ongoing Phase 1/2a trials. This type of announcement, which summarizes key results and points to a future presentation or publication, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is primarily focused on releasing key financial/clinical performance highlights (results) rather than being a full, comprehensive report (like 10-K or IR), ER is a strong candidate. However, the text explicitly states that the full poster will be posted to the company's website shortly after the presentation, and the document itself is a press release announcing the presentation of data. Given the content is a summary of clinical trial results and future presentation plans, it fits best as an Earnings Release (ER) which typically covers period results/updates, or potentially a Regulatory Filing (RNS) if it doesn't strictly qualify as an earnings announcement. Since it details clinical efficacy metrics which are often the core of periodic updates, ER is chosen over the general RNS fallback. The document length (8416 chars) is substantial enough to be more than just a brief announcement of a report being available (which would suggest RPA). FY 2024
2024-05-14 English
BioInvent presenterar ytterligare lovande fas 1/2a-data vid EHA 2024 för BI-1206 med rituximab i NHL
Report Publication Announcement Classification · 95% confidence The document is a press release dated May 14, 2024, announcing that clinical data for the drug candidate BI-1206 will be presented at the European Hematology Association (EHA) congress in June 2024. It details preliminary Phase 1/2a results (CR, PR, SD rates) and mentions that the full poster will be published on the company website after the presentation. The text explicitly states, 'Den fullständiga postern kommer att publiceras på bolagets hemsida [...] strax efter presentationen i juni.' This structure—an announcement about upcoming presentation of data, often including key highlights and a link to where the full material will eventually reside—is characteristic of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since it is announcing the publication/presentation of detailed scientific data (which would likely be an IP or AR if provided in full), and this document itself is the announcement, RPA is the most appropriate classification based on Rule 2 (Menu vs Meal). It is not the full report, but the announcement of its release/presentation.
2024-05-14 Swedish
Resolutions at BioInvent’s Annual General Meeting 2024
AGM Information Classification · 99% confidence The document explicitly details the 'Resolutions at BioInvent's Annual General Meeting 2024'. It covers the election of board members, approval of financial statements, decisions on dividends, board fees, and the implementation of an incentive program, all of which are core components of an AGM outcome report. This directly matches the definition for AGM Information (AGM-R). Although it is a press release format, the content is the official summary of the meeting's resolutions.
2024-05-03 English
Beslut på BioInvents årsstämma 2024
AGM Information Classification · 98% confidence The document is titled "Beslut på BioInvents årsstämma 2024" (Decisions at BioInvent's Annual General Meeting 2024). It details the resolutions passed at the Annual General Meeting (AGM), including board elections, approval of financial statements, decisions on dividends, remuneration reports, and the establishment of an incentive program. This content directly relates to the proceedings and outcomes of an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). Although it is a summary of decisions, it is not merely an announcement of a report's publication (RPA) but the core content of the AGM outcome itself.
2024-05-03 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.